| Literature DB >> 22461978 |
Ana Cristina Araújo Lemos Silva1, Blenda Sousa Carli Rodrigues, Adilha Misson Rua Micheletti, Sebastião Tostes, Antonio Carlos Oliveira Meneses, Mário Leon Silva-Vergara, Sheila Jorge Adad.
Abstract
A retrospective study of central nervous system (CNS) in 284 autopsy AIDS cases in Brazil (1989-2008) divided into 3 groups: A (without antiretroviral treatment: 163 cases); B (other antiretroviral therapies: 76 cases); C (HAART for 3 months or more: 45 cases). In 165 (58.1%) cases, relevant lesions were found, predominantly infections (54.2%); the most frequent was toxoplasmosis (29.9%) followed by cryptococcosis (15.8%), purulent bacterial infections (3.9%), and HIV encephalitis (2.8%); non-Hodgkin lymphomas occurred in 1.4% and vascular lesions in 1.1%. There was no difference when compared the frequency of lesion among the groups; however, toxoplasmosis was less common while HIV encephalitis was more frequent in group C related to A. CNS lesions remain a frequent cause of death in AIDS; however, the mean survival time was four times greater in group C than in A. In 91 (55.1%) of 165 cases with relevant brain lesions (or 32% of the total 284 cases), there was discordance between pre- and postmortem diagnosis; disagreement type 1 (important disease that if diagnosed in life could change the patient prognosis) occurred in 49 (53.8%) of 91 discordant cases (17.6% of the total 284) indicating the autopsy importance, even with HAART and advanced diagnostics technologies.Entities:
Year: 2012 PMID: 22461978 PMCID: PMC3296154 DOI: 10.1155/2012/186850
Source DB: PubMed Journal: AIDS Res Treat ISSN: 2090-1240
Relevant morphological lesions in the central nervous system in 284 autopsies of patients with acquired immunodeficiency syndrome, according to the study groups.
| Type of lesion | Group A | Group B | Group C | Total | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Toxoplamosis | *59 | 36.2% | 18 | 23.7% | *8 | 17.8% | 85 | 29.9% |
| Amebiasis | 0 | 0 | 1 | 1.3% | 0 | 0 | 1 | 0.3% |
|
|
|
|
|
|
|
|
|
|
| Cryptococosis | 27 | 16.6% | 11 | 14.5% | 7 | 15.6% | 45 | 15.8% |
| Histoplasmosis | 2 | 1.2% | 0 | 0 | 0 | 0 | 2 | 0.7% |
| Paracoccidioidomycosis | 1 | 0.6% | 0 | 0 | 0 | 0 | 1 | 0.3% |
| Sporotrichosis | 0 | 0 | 1 | 1.3% | 0 | 0 | 1 | 0.3% |
|
|
|
|
|
|
|
|
|
|
| Meningitis/encephalitis/abscess | 5 | 3.1% | 3 | 3.9% | 3 | 6.7% | 11 | 3.9% |
| Tuberculosis/mycobacteriosis | 4 | 2.4% | 0 | 0 | 0 | 0 | 4 | 1.4% |
|
|
|
|
|
|
|
|
|
|
| Cytomegalovirus | 5 | 3.1% | 1 | 1.3% | 1 | 2.2% | 7 | 2.5% |
| Nodular encephalitis | 2 | 1.2% | 1 | 1.3% | 0 | 0 | 3 | 1.2% |
| HIV | *3 | 1.8% | 0 | 0 | *5 | 11.1% | 8 | 2.8% |
| JC | 1 | 0.6% | 0 | 0 | 0 | 0 | 1 | 0.3% |
|
|
|
|
|
|
|
|
|
|
| Lymphoid Neoplasms | 4 | 2.4% | 1 | 1.3% | 0 | 0 | 5 | 1.8% |
| Meningiomas | 2 | 1.2% | 0 | 0 | 0 | 0 | 2 | 0.7% |
|
|
|
|
|
|
|
|
|
|
| Concomitant Lesions | 11 | 3.9% | 1 | 0.4% | 2 | 0.7% | 14 | 4.9% |
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| Subtotal normal or without relevants lesions | 59 | 36.2% | 39 | 51.3% | 21 | 46.7% | 119 | 41.9% |
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
Group A: without use of any antiretroviral medication; B: 1 or 2 antiretroviral therapy or HAART for any time less than 3 months; C: HAART for 3 months or more; *P < 0.05; χ 2 test. Nonrelevant lesions occurred in 103 (36.3%) of 284 cases, represented by focal alterations, scarring or just edema related to the final events; in only 16 (5.6%) cases the brain was completely normal. †Among the cases with bacterial infection in group A, one patient showed concomitant infection by coccus and mycobacteria in different regions of the CNS (9 bacterial infections/8 patients).
Average values of survival time (months) after diagnosis of HIV infection in 261 of 284 autopsies of acquired immunodeficiency syndrome, in which it was possible to obtain this information, according to the study groups.
| Group | A | B | C | All cases |
|---|---|---|---|---|
|
|
|
|
| |
| Mean | 11.2 | 25.8 | 49.1 |
|
| Standard deviation | 26.1 | 30.6 | 30.0 |
|
| Median | 1 | 11 | 48 |
|
| Min-max value | 0–192 | 0–132 | 6–144 |
|
Group A: without use of any antiretroviral medication; B: 1 or 2 antiretroviral therapy or HAART for any time less than 3 months; C: HAART for 3 months or more; min: minimum, max: maximum. N: number of cases it was possible to obtain the survival time. Kruskal-Wallis/Dunn: P < 0.001 when comparing all groups.
(a)
| Pre-HAART |
| Les | Tox | Cry | CMV | HIV | PML | Nod Enc | Lym | Vas | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Moskowitz et al. 1984 Miami, USA [ |
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||||
| Anders et al. 1986 Los Angeles, USA [ |
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||||
| Petito et al. 1986 New York, USA [ |
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||||
| Budka et al. 1987 Europe [ |
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||||
| Lang et al .1989 Switzerland [ |
|
|
|
|
|
|
|
|
| ||
|
| |||||||||||
| Chimelli et al. 1992 Rio/S.Paulo, Brazil [ |
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||||
| Wainstein et al. 1992 P. Alegre, Brazil [ |
|
|
|
|
|
|
|
|
|
| |
(b)
| Post-HAART |
|
| Les | Tox | Cry | CMV | HIV | PML | Nod Enc | Lym | Vas |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Masliah et al. 2000 California, USA [ |
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
|
Jellinger et al. 2000 Austria [ |
|
| |||||||||
| 1984–1992 | 190 | 24.0 | 3.1 | 17.4 | 16.1 | 5.7 | 3.1 | 6.3 | 8.8 | ||
| 1993–1995 | 162 | 80.0 | 20.4 | 4.4 | 20.4 | 13.8 | 8.7 | 8.1 | 11.2 | 6.8 | |
| 1996–1999 | 98 | 60.0 | 8.0 | 4.0 | 11.0 | 15.0 | 5.0 | 0 | 6.0 | 10.0 | |
|
| |||||||||||
|
Morgello et al. 2002 New York, USA [ |
|
|
|
|
|
| |||||
| 1979–1986 | 88 | 59.0 | 10.0 | 4.0 | 1.0 | ||||||
| 1987–1995 | 207 | 58.0 | 17.0 | 0 | 5.0 | ||||||
| 1996–2000 | 99 | 80.0 | 15.0 | 2.0 | 7.0 | ||||||
|
| |||||||||||
|
Neuenburg et al. 2002 Germany [ |
|
|
|
|
|
|
|
|
|
| |
| 1985-1986 | 32 | 9.4 | 3.1 | 21.9 | 34.4 | 6.3 | 15.6 | ||||
| 1987–1992 | 170 | 7.7 | 1.2 | 35.9 | 33.5 | 1.2 | 11.2 | ||||
| 1993–1995 | 127 | 5.5 | 0.8 | 15.7 | 37.0 | 7.1 | 7.9 | ||||
| 1996–1999 | 42 | 7.1 | 0 | 9.5 | 59.5 | 0 | 2.4 | ||||
|
| |||||||||||
|
Vago et al. 2002 Italy [ |
|
|
| ||||||||
| 1984–1987 | 119 | 54.0 | |||||||||
| 1988–1994 | 1116 | 32.0 | |||||||||
| 1995-1996 | 256 | 18.0 | |||||||||
| 1997–2000 | 106 | 15.0 | |||||||||
|
| |||||||||||
|
Gray et al. 2003 France [ |
|
| |||||||||
| 1985–1991 | |||||||||||
| 1992–1996 | |||||||||||
| 1997–2002 | 23 | 13.0 | 0 | 8.7 | 17.4 | 17.4 | 13.0 | ||||
|
| |||||||||||
|
Walsh et al. 2004 Canada [ |
|
|
|
|
|
|
|
|
|
|
|
| 1 | 5 | 60.0 | 60.0 | 20.0 | 0 | ||||||
| 2 | 11 | 0 | 27.3 | 27.3 | 18.2 | ||||||
|
| |||||||||||
|
Silva et al. (current study) 2011 Uberaba, Brazil [ |
|
|
|
|
|
|
|
|
|
|
|
| A | 163 | 63.8 | 36.2 | 16.6 | 3.1 | 1.8 | 0.6 | 1.2 | 1.8 | 0 | |
| B | 76 | 48.7 | 23.7 | 14.5 | 1.3 | 0 | 0 | 1.3 | 1.3 | 1.3 | |
| C | 45 | 53.3 | 17.8 | 15.6 | 2.2 | 11.1 | 0 | 0 | 0 | 4.4 | |
N: number of cases, NG: number of cases in each group; P: period; the last period corresponds to HAART; Les: lesion; all lesions are expressed in percentages; Tox: toxoplasmosis; Cry: cryptococcosis, CMV: cytomegalovirus, HIV: HIV encephalitis/leukoencephalopathy; PML: progressive multifocal leukoencephalopathy JC virus; Lym: primary central nervous system non-Hodgkin lymphoma; Vas: vascular lesion (infarction, hemorrhage). Only Gray et al. Walsh et al. and the current study separated the groups by analyzing the therapy used in each patient; the others divided the groups according to treatment available at the time.